Etg Warszawa Sp. z o.o.

Warsaw 68 trials 28 recruiting

68 Registered trials

28 Currently recruiting

Organisation

Etg Warszawa Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100040846

Address

Ul. Wynalazek 4, 02-677, Poland

Departments

.
#40604:ETG Neuroscience
#45006: ETG Warszawa
202-ETG Warszawa
2703: ETG Warszawa
2901 : Ortopedia
403_ETG Warszawa
40604: Dermatology
40604: ETG Warszawa
616009: ETG Warszawa
Dermatology
ETG Warszawa
General Medicine
N/A
NA
NA/ND
No Department
not applicable/nie dotyczy
Poradnie ETG Warszawa
Private Practice

Clinical trials at this site (68)

Search interface

A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adoles… Recruiting

2024-518156-24-00 Atopic Dermatitis 5 2025-11-10
A randomized, phase 3 multicenter study to confirm the clinical efficacy of linaprazan glurate compared to lansoprazole in participants with… Recruiting

2024-518714-31-00 Erosive esophagitis (EE) due to gastroesophageal reflux 5 2025-10-03
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Psoriatic Arthritis 5 2025-06-26
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2024-517513-32-00 Sjögren’s Syndrome 5 2025-05-16
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Recruiting

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting

2023-508158-24-00 Moderately to Severely Active Crohn’s Disease 4 2024-06-25
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease Ended

2025-521791-63-00 Moderately to Severely Active Rheumatologic Disease 4 2025-12-18
A Study to Compare Different Doses of RO7795081 with a Placebo or Semaglutide in People with Type 2 Diabetes Ended

2024-520322-11-00 Type 2 Diabetes Mellitus (T2D) 4 2025-09-29
Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease Ended

2024-516295-14-00 Treatment of Sjögren’s disease 4 2025-09-17
A Trial to Study the Safety and Efficacy of a New Drug Combination for Weight Loss While Maintaining Muscles Ended

2024-519561-22-00 Obesity 4 2025-07-07
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation t… Ended

2023-510458-18-00 Asthma 6 2025-03-11
A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended

2024-511738-11-00 Psoriatic arthritis 5 2024-12-18
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510341-19-00 acne vulgaris 5 2024-11-14
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper… Ended

2023-508670-28-00 Hypertension 5 2024-08-26
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended

2022-502518-98-00 nonsegmental vitiligo 5 2024-04-26
Selective Treatment of Oral Povorcitinib in Vitiligo Study 1 (STOP-V1) Ended

2023-505782-86-00 Vitiligo 5 2024-04-23
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08